Biodexa Pharmaceuticals Plc
BDRX
$7.77
-$0.57-6.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.11M | 1.05M | 2.08M | 2.11M | 1.38M |
| Gross Profit | -1.11M | -1.05M | -2.08M | -2.11M | -1.38M |
| SG&A Expenses | 1.59M | 1.50M | 1.13M | 1.14M | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.00K | -17.00K | -19.90K | -20.20K | -- |
| Total Operating Expenses | 2.68M | 2.53M | 3.19M | 3.24M | 2.66M |
| Operating Income | -2.68M | -2.53M | -3.19M | -3.24M | -2.66M |
| Income Before Tax | -2.65M | -2.50M | -1.63M | -1.66M | -2.17M |
| Income Tax Expenses | -110.20K | -103.90K | -80.00K | -81.30K | -78.80K |
| Earnings from Continuing Operations | -2.54M | -2.40M | -1.55M | -1.58M | -2.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.54M | -2.40M | -1.55M | -1.58M | -2.09M |
| EBIT | -2.68M | -2.53M | -3.19M | -3.24M | -2.66M |
| EBITDA | -2.63M | -2.48M | -3.15M | -3.21M | -2.62M |
| EPS Basic | -1.01M | -948.57K | -2.34M | -2.38M | -6.36M |
| Normalized Basic EPS | -6.56 | -6.19 | -15.38 | -15.63 | -41.25 |
| EPS Diluted | -1.01M | -948.57K | -2.34M | -2.38M | -6.36M |
| Normalized Diluted EPS | -6.56 | -6.19 | -15.38 | -15.63 | -41.25 |
| Average Basic Shares Outstanding | 252.70K | 252.70K | 66.20K | 66.20K | 32.80K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |